Overview

Our lead product, NOVade™ has demonstrated success in both pre-clinical and clinical settings in treating cancer.  NOVade™ addresses the consequences of hypoxia in cancer; disease progression through metastisis, increased invasiveness and resistance to treatment. Initial results demonstrated clinical efficacy through the stabilization of patients’ PSA levels. 

Nometics Inc. plans to initiate additional clinical trials for NOVade™ in prostate cancer and other grievous conditions including non-small cell lung and colorectal cancer.